CRYSTAL Study: A Multi-Center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries.
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Aug 2018
At a glance
- Drugs Sirolimus (Primary) ; Everolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms CRYSTAL
- Sponsors Micell Technologies
- 14 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 31 Mar 2019.
- 29 May 2018 New trial record
- 23 May 2018 According to a Micell Technologies media release, the company is preparing an FDA IDE submission for this study.